

HBGVs established by WHO, ATSDR and Health Canada

In this guide

[In this guide](#)

1. [Executive Summary - Annex 1 to TOX/2025/23](#)
2. [Background and scope of discussion - Annex 1 to TOX/2025/23](#)
3. [Properties of antimony and sources in drinking water - Annex 1 to TOX/2025/23](#)
4. [Oral toxicity data for antimony - Annex 1 to TOX/2025/23](#)
5. [HBGVs established by WHO, ATSDR and Health Canada - Annex 1 to TOX/2025/23](#)
6. [Discussion - Annex 1 to TOX/2025/23](#)
7. [Overall Conclusion - Annex 1 to TOX/2025/23](#)
8. [List of abbreviations and their full meanings - Annex 1 to TOX/2025/23](#)
9. [References - Annex 1 to TOX/2025/23](#)
10. [Annex A - Annex 1 to TOX/2025/23](#)
11. [Annex A References - Annex 1 to TOX/2025/23](#)

This is a draft position statement for discussion. This does not represent the views of the Committee and should not be cited.

25. WHO selected a NOAEL of 6,000 µg Sb/kg bw/day from the Poon et al. (1998) study, as recommended by Lynch et al. (1999), for decreased body weight gain and reduced food and water intake. A UF of 1,000 (100 for interspecies and intraspecies differences and 10 for the short duration of the study) was applied to the NOAEL resulting in the TDI of 6.0 µg/kg bw/day (WHO 2003).

26. ATSDR selected a NOAEL of 60 µg Sb/kg bw/day for decreases in serum glucose levels in female rats observed in the Poon et al. (1998). A UF of 100 (10 for extrapolation from animals to humans and 10 for human variability)

was applied to derive an intermediate-duration (15 – 365 days) oral Minimal Risk Level (MRL) of 0.6 µg/kg bw/day (ATSDR 2019).

27. Health Canada also selected a NOAEL of 60 µg Sb /kg bw/day from the study by Poon et al. (1998), based on observed histopathological changes in the liver (anisokaryosis) and alterations in serum biochemistry indicative of liver effects. A UF of 300 was applied (10 for interspecies variation, 10 for intraspecies variation and 3 for the use of a subchronic study) resulting in a TDI of 0.2 µg/kg bw/day (Health Canada, 2024).

28. More information on the derivation of the HBGVs for WHO, ATSDR and Health Canada is available in the COT discussion paper [TOX/2024/38](#).